Which combination is better for a severe carbapenem‑resistant Gram‑negative infection with suspected or confirmed metallo‑β‑lactamase: aztreonam plus Zerbaxa (ceftolozane/tazobactam) or aztreonam plus Zavicefta (ceftazidime‑avibactam)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Zavicefta (Ceftazidime-Avibactam) + Aztreonam is Superior

For severe carbapenem-resistant Gram-negative infections with suspected or confirmed metallo-β-lactamase production, use Zavicefta (ceftazidime-avibactam) plus aztreonam rather than Zerbaxa (ceftolozane-tazobactam) plus aztreonam. This recommendation is based on guideline consensus, mechanistic rationale, and clinical outcome data demonstrating mortality benefit.

Why Zavicefta + Aztreonam is the Preferred Combination

Guideline-Based Recommendations

The most recent guidelines specifically endorse ceftazidime-avibactam plus aztreonam for MBL-producing CRE:

  • ESCMID 2022 guidelines suggest aztreonam and ceftazidime-avibactam combination therapy for severe CRE infections carrying metallo-β-lactamases (conditional recommendation, moderate evidence) 1

  • Chinese guidelines 2023 recommend ceftazidime-avibactam combined with aztreonam as a preferential choice for MBL-producing CRE infections, demonstrating 30-day mortality of 19.2% versus 44% with other agents (HR: 0.37,95% CI 0.13-0.74) 2

Mechanistic Superiority

The combination works through complementary mechanisms:

  • Aztreonam is not hydrolyzed by metallo-β-lactamases but is susceptible to other β-lactamases
  • Avibactam (in Zavicefta) protects aztreonam from degradation by serine β-lactamases (including KPC, OXA-48, AmpC, ESBL)
  • Tazobactam (in Zerbaxa) has weaker inhibitory activity against these enzymes compared to avibactam

Clinical Outcomes Data

Recent meta-analysis and clinical studies demonstrate:

  • Mortality reduction: Ceftazidime-avibactam plus aztreonam showed 30-day mortality of 19.2% versus 44% with polymyxins or other agents (p=0.007) 2
  • Clinical cure rates: 77.5% in critically ill patients with MBL-producing infections 2
  • Lower treatment failure: HR 0.30 (95% CI 0.14-0.65) 2
  • Shorter hospital stay: HR 0.49 (95% CI -0.82) 2

In Vitro Synergy Evidence

Laboratory studies confirm superior activity:

  • Ceftazidime-avibactam plus aztreonam restored susceptibility in 86% of MBL-producing Enterobacterales 3
  • Ceftolozane-tazobactam plus aztreonam restored susceptibility in only 20% of MBL-producing Enterobacterales 3
  • Against Klebsiella pneumoniae (the most common MBL producer), synergy rates exceeded 90% with ceftazidime-avibactam plus aztreonam 4

Critical Implementation Points

When to Use This Combination

Use when you have:

  • Confirmed MBL production (NDM, VIM, IMP types) by molecular testing or phenotypic methods (mCIM/eCIM)
  • Suspected MBL in severe infection from high-prevalence areas while awaiting confirmation
  • Severe infections: bloodstream infections, hospital-acquired pneumonia, complicated intra-abdominal infections

Why Zerbaxa + Aztreonam is Inadequate

Ceftolozane-tazobactam (Zerbaxa) is not designed for MBL-producing organisms:

  • Tazobactam provides insufficient protection against the diverse β-lactamases co-produced with MBLs
  • No guideline recommends this combination for MBL infections
  • In vitro data shows poor synergy (only 20% susceptibility restoration) 3
  • Zerbaxa is indicated for difficult-to-treat Pseudomonas aeruginosa without MBL 1, 5

Dosing Regimen

Based on the clinical studies showing mortality benefit 2:

  • Ceftazidime-avibactam: 2.5 g IV every 8 hours (infused over 2 hours)
  • Aztreonam: 2 g IV every 8 hours (infused over 3 hours)
  • Adjust for renal function as needed

Common Pitfalls to Avoid

  1. Don't use Zerbaxa for MBL infections - it lacks adequate β-lactamase inhibition for this resistance mechanism
  2. Confirm carbapenemase type - if KPC or OXA-48 (not MBL), ceftazidime-avibactam alone may suffice
  3. Don't delay therapy - start empirically if MBL suspected in severe infection from endemic areas
  4. Monitor for resistance - though rare with this combination, resistance can emerge in Pseudomonas species 4

Geographic Considerations

In regions where:

  • NDM predominates (South Asia, Middle East, China): This combination is essential
  • KPC predominates (parts of Europe, USA): Ceftazidime-avibactam monotherapy may be adequate
  • Mixed epidemiology: Use combination empirically for severe infections

Evidence Quality Assessment

While guidelines rate this as "very low quality evidence" due to observational study design 2, the consistency of findings across multiple studies, the magnitude of mortality benefit (HR 0.37), and the mechanistic rationale provide strong support for this recommendation in clinical practice. The alternative (polymyxins) carries significant nephrotoxicity and inferior outcomes.

References

Related Questions

For a severe carbapenem‑resistant Gram‑negative infection, especially metallo‑β‑lactamase‑producing, should I use colistin or aztreonam plus ceftazidime‑avibactam (Zerbaxa) as the preferred therapy?
Can ceftazidime‑avibactam (Zavicefta) combined with aztreonam effectively treat urinary infections caused by Pseudomonas aeruginosa and Klebsiella species?
In a severe carbapenem‑resistant Gram‑negative infection suspected of producing a metallo‑β‑lactamase, is aztreonam plus ceftazidime‑avibactam (Zerbaxa) preferable to ceftazidime‑avibactam alone (Zavicefta)?
What antibiotic regimen is appropriate for a patient with an infected amputation site who is allergic to meropenem and vancomycin?
What antibiotics should be used to treat carbapenem‑resistant Pseudomonas aeruginosa isolated from broncho‑alveolar lavage in an adult patient with normal renal function?
Can pneumonia cause a runny nose (rhinorrhea)?
In a severe carbapenem‑resistant Gram‑negative infection suspected of producing a metallo‑β‑lactamase, is aztreonam plus ceftazidime‑avibactam (Zerbaxa) preferable to ceftazidime‑avibactam alone (Zavicefta)?
Which antidepressants are compatible with tamoxifen (i.e., do not strongly inhibit CYP2D6)?
What is walking pneumonia, including its typical cause, clinical presentation, and first‑line treatment?
What are the guidelines for using primaquine in malaria treatment, including dosing, contraindications, and monitoring?
In a 57-year-old woman with new‑onset uncontrolled diabetes mellitus, a normal pancreas on abdominal CT, and no personal or family history of diabetes, what additional tests should be performed to evaluate for autoimmune diabetes or other etiologies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.